FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely immunology, and can be used to produce an adjuvant composition consisting of chitosan and oligodeoxynucleotide. Adjuvant composition contains chitosan with molecular weight in range of 200 to 1000 kDa, degree of deacetylation from 75 to 98 %, polydispersity index of not more than 2.0, level of endotoxins and extraneous protein of less than 100 EU/ml and 0.05 %, respectively, A oligodeoxynucleotide is a synthetic oligodeoxynucleotide, which consists of 5 repeating segments of CG nucleotides with thiophosphoryl bonds in internucleotide phosphates; at ratio of components of chitosan: synthetic oligodeoxynucleotide (20–50):1.
EFFECT: use of the given invention provides high immunogenicity and protective effect when adding an adjuvant composition to vaccines against infectious agents of bacterial and viral origin.
3 cl, 5 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD TO INCREASE IMMUNOGENICITY OF INACTIVATED FLUE VACCINE | 2007 |
|
RU2323742C1 |
| OLIGOHITOZANE DERIVATIVES AS ADJUVANTS FOR VACCINES | 2015 |
|
RU2589702C1 |
| METHOD OF FORMING POST-VACCINATION IMMUNE AGAINST INFLUENZA VIRUS IN PATIENTS WITH GENERAL VARIABLE IMMUNE DEFICIENCY | 2022 |
|
RU2800858C1 |
| METHOD FOR IMPROVING IMMUNOGENICITY OF COLD-ADAPTED LIVE INFLUENZA VACCINE | 2010 |
|
RU2465006C2 |
| ADJUVANT FOR ANTI-VIRAL VACCINES | 2017 |
|
RU2676266C2 |
| IMPROVED IMMUNOLOGICAL COMPOSITION | 2012 |
|
RU2664730C2 |
| INFLUENZA VACCINE AND METHOD FOR PREPARING IT | 2010 |
|
RU2446824C2 |
| WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
| METHOD FOR OBTAINING A TETRAVALENT VACCINE FOR THE PREVENTION OF INFLUENZA | 2020 |
|
RU2754398C1 |
| METHOD OF OBTAINING INACTIVATED VACCINE AGAINST COVID-19 AND VACCINE OBTAINED BY METHOD | 2023 |
|
RU2810740C1 |
